SEC Filing Timeline
8-KJun 15, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJun 10, 2026
Shareholder vote results · Items 5.07
10-QMay 11, 2026
Quarterly report
8-KMay 11, 2026
Earnings release · Items 2.02,9.01
8-KApr 30, 2026
Material agreement · Items 1.01,2.02,9.01
DEFA14AApr 30, 2026
Additional proxy
DEF 14AApr 30, 2026
Proxy statement
424B5Apr 29, 2026
Prospectus / offering
424B5Apr 27, 2026
Prospectus / offering
8-KApr 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KApr 10, 2026
Charter/bylaws amendment · Items 5.03,9.01
424B5Mar 02, 2026
Prospectus / offering
8-KMar 02, 2026
Material agreement · Items 1.01,7.01,8.01,9.01
10-KFeb 26, 2026
Annual report
8-KFeb 26, 2026
Earnings release · Items 2.02,9.01
Recent News (Finnhub)
The Disinflation Trade Has A New Address: Genomics
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial…